Evaluation of the Antalgic Effect of Puressentiel Joints and Muscles - Gel on Joint Pain of the Knee

NCT ID: NCT04736563

Last Updated: 2021-02-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial aims to evaluate the antalgic effect of Puressentiel Joints and Muscles - Gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. The evaluation of the puressentiel antalgic effect Joints and Muscles - Gel with 14 essential oils will be done by an algo-functional score of WOMAC based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale EVA (graduated from 1 to 10) of the pain by self-assessment of the patient during the consultation and the number of daily analgesics and anti-inflammatory drugs (secondary criteria).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial aims to evaluate the antalgic effect of Puressentiel Joints and Muscles - Gel with 14 essential oils for 12 weeks on knee joint pain in 45 patients suffering from chronic pain related to arthritis of the knee. The patients included in the study will be consultants from the Department of Physical Medicine, Rehabilitation and Sports Trauma at Foch Hospital in Suresnes and will have to present chronic pain related to arthritis of the knee either with or without antalgic and anti-inflammatory treatment. The evaluation of the puressentiel antalgic effect Joints and Muscles - Gel with 14 essential oils will be evaluated by an algo-functional score of WOMAC based on items of pain, joint stiffness and locomotor function (main criterion), a visual analog scale EVA (graduated from 1 to 10) of the pain by self-assessment of the patient during each visit and the number of daily antalgic and anti-inflammatory drugs (secondary criteria).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Joint Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

open single arm study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with painful arthritis of the knee

Administration of joints and muscle gel Puressentiel containing of 14 essential oils

Group Type EXPERIMENTAL

Joint and muscle gel Puressentiel

Intervention Type DEVICE

To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Joint and muscle gel Puressentiel

To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject smust be able to understand the terms of the written informed consent and must agree to date and sign it before any study procedure is carried out,
* Patient having signed the informed consent
* Aged 45 to 90
* With chronic osteoarthritis of the knee
* Patient with or without analgesic and anti-inflammatory treatment

Exclusion Criteria

* Patient at the stage of surgical osteoarthritis (grade 4 plus limitation of amplitude)
* Patient with a limited walking perimeter (\<100m) for any reason whatsoever
* Patient allergic to one of the components of the study product
* Patient not benefiting from social security
* Patient cannot be followed for the duration of the study
* Participation in another clinical trial within 30 days before V0
* Subjects who cannot understand or perform study procedures.
* Pregnant or breastfeeding women
* People with a history of convulsive or epileptic disorders
* People allergic to salicylates.
Minimum Eligible Age

45 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Marco Pacchioni

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marco Pacchioni

President Puressentiel laboratory

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elisabeth Simon, Pharm Dr

Role: STUDY_DIRECTOR

Puressentiel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Foch

Suresnes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elisabeth Simon, MD

Role: CONTACT

33611815878

Elisabeth Simon

Role: CONTACT

0144405528

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas Barizien, MD

Role: primary

0611815878

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Puressentiel laboratory

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Knee Osteoarthritis and Spa Therapy
NCT06617975 RECRUITING NA